The addition of pembrolizumab to concurrent chemoradiotherapy for high-risk locally advanced cervical cancer does not harm quality of life, according to patient-reported outcome analyses from the KEYNOTE-A18 trial. The trial showed a 30% reduction in the risk for progression with pembrolizumab compared to placebo, with favorable overall survival trends. Patient-reported outcome instruments used in the study showed no meaningful differences in quality of life between the pembrolizumab and placebo groups. The data support pembrolizumab plus concurrent chemoradiotherapy as a new standard of care for these patients, with no significant impacts on quality of life.
Source link
QOL Not Harmed With Add-On Pembrolizumab in Cervical Cancer
